PDE5抑制剂与黑色素瘤风险的相关性研究进展  

Recent advance in the correlation between PDE5 inhibitors and the risk of melanoma

作　　者：陈红英[1] 许乃馨 黄引 曹德宏[2] 董强(综述)[2] 魏强(审校)[2] CHEN Hongying;XU Naixin;HUANG Yin;CAO Dehong;DONG Qiang;WEI Qiang(Research Core Facility, West China Hospital, Sichuan University, Chengdu 610041, China;Department of Urology,Institute of Urology, West China Hospital, Sichuan University Chengdu 610041, China)

机构地区：[1]四川大学华西医院公共实验技术中心,四川成都610041 [2]四川大学华西医院泌尿外科·泌尿外科研究所,四川成都610041

出　　处：《西部医学》2022年第2期309-312,共4页Medical Journal of West China

基　　金：国家自然科学基金(82000721)。

摘　　要：5型磷酸二酯酶抑制剂(PDE5抑制剂)是治疗勃起功能障碍的首选药物,其通过选择性抑制PDE5的活性,减少cGMP的降解,扩张阴茎海绵体血管,从而维持男性勃起反应。目前,部分基础研究表明PDE5抑制剂的作用机制可能会影响皮肤细胞的信号通路,导致患者黑色素瘤的风险增加。此外,较多临床研究也对PDE5抑制剂和黑色素瘤发病风险的相关性进行了评估,但目前尚未得出明确一致的结论。本文就上述研究进展进行综述。Phosphodiesterase type 5(PDE5)inhibitor is the drug of choice for the treatment of erectile dysfunction.It selectively inhibits the activity of PDE5,reduces the degradation of cGMP,and causes the vasodilation of the corpus cavernosum,thereby maintaining the male erectile response.At present,some studies have shown that the mechanism of action of PDE5 inhibitor may affect the signaling pathways of skin cells,leading to an increased risk of melanoma in patients.In addition,many epidemiological studies have also evaluated the association between PDE5 inhibitor and the risk of melanoma,but no clear consensus has yet been reached.This article reviews the progress of the above research.

关 键 词：PDE5抑制剂 黑色素瘤 勃起功能障碍 

分 类 号：R739.5[医药卫生—肿瘤]